- Data on file at Seikagaku corporation.
- Strand, V. et al. A multicenter, randomized controlled trial comparing a single intra-articular injection of Gel-One, a new cross-linked formulation of hyaluronic acid, to phosphate buffered saline for treatment of osteoarthritis of the knee. Osteoarthritis and Cartilage. 20: 350-356, 2012.
- Strand, V., et al. Effectiveness and Safety of a Multicenter Extension and Retreatment Trial of Gel-200 in Patients with Knee Osteoarthritis. Cartilage. 3(4): 297-304, 2012.
- Lot release testing for protein bacterial endotoxin, and DNA (viscosity decline) performed by Seikagaku Corporation.
- Strand, V., et al. Evidence for safety of retreatment with a single intra-articular injection of Gel-200 for treatment of osteoarthritis of the knee from the double-blind pivotal and open-label retreatment clinical trials. BMC Musculoskeletal Disorders. 17:240, 2016.
- K. Yoshioka et al. Pharmacological effects of novel cross-linked hyaluronate, Gel-200, in experimental animal models of osteoarthritis and human cell lines. Osteoarthritis and Cartilage 2014; 22:879-887.
Discover the Power of ONE with Gel-One® Cross-linked Hyaluronate
Effective Pain Relief.1
Easy-to-Use.2
Proven Safety Profile.2-5
Gel-One® Hyaluronate is a 100% cross-linked gel, allowing for better cushioning and greater product durability1 in a single 3mL injection, giving healthcare providers confidence in addressing mild to moderate OA of the knee with a safe, effective and complete treatment.
Download the Clinical Paper to:
- Learn more about how Gel-One is the only single 3mL injection2 on the market that offers your patients up to 26 weeks of pain relief.3
Yes, I want access to the Clinical Value of Gel-One:
Disclaimer
Indications For Use: Gel-One Hyaluronate is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to non-pharmacologic therapy, nonsteroidal anti-inflammatory drugs (NSAIDs) or simple analgesics, e.g., acetaminophen.
Important Safety Information: Before using Gel-One Hyaluronate, ask your patients if they are allergic to hyaluronan products, cinnamon, or products from birds, such as feathers, eggs, and poultry. Gel-One Hyaluronate is only for injection into the knee, performed by a doctor or other qualified healthcare professional. Gel-One Hyaluronate injection should not be used in the presence of skin disease or infection around the area where the injection will be given. Gel-One Hyaluronate has not been tested to show pain relief in joints other than the knee or for conditions other than OA. Gel-One Hyaluronate has not been tested in patients who are pregnant, mothers who are nursing, or anyone under the age of 21. Strenuous or prolonged weight-bearing activities after treatment are not recommended. The effectiveness of repeat treatment cycles of Gel-One Hyaluronate has not been established. The side effects most commonly seen after injection of Gel-One Hyaluronate in the clinical trial were knee pain, swelling and/or knee effusion. These reactions are generally mild and do not last long. For complete instructions for use, see the package insert and visit www.zimmerbiomet.com.
All content herein is protected by copyright, trademarks and other intellectual property rights, as applicable, owned by or licensed to Zimmer Biomet or its affiliates unless otherwise indicated, and must not be redistributed, duplicated or disclosed, in whole or in part, without the express written consent of Zimmer Biomet.
This material is intended for healthcare professionals. Distribution to any other recipient is prohibited. Zimmer Biomet does not practice medicine.
For indications, contraindications, warnings, precautions, potential adverse effects and patient counselling information, see the package insert or contact your local representative; visit www.zimmerbiomet.com for additional product information.
Legal Manufacturer:
Seikagaku Corporation
6-1, Marunouchi 1-chome, Chiyoda-ku
Tokyo 100-0005, Japan
©2026 Zimmer Biomet